The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Share News (N4P)

Share Price Information for N4 Pharma Plc (N4P)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.80
Bid: 0.75
Ask: 0.85
Change: 0.00 (0.00%)
Spread: 0.10 (13.333%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 0.80
N4P Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Boku launches in Germany; Focusrite trading well

Tue, 14th Sep 2021 14:31

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Boku Inc - mobile payment and identity company based in California, US - Launches its Verify and Authenticate solutions in Germany. Says both solutions are integrated with O2, Telekom Deutschland, and Vodafone service providers. Expands total global coverage for its verification and authentication services, which have launched in 20 countries. Says it final earn-out payment, related to the acquisition of Fortumo Holdings Inc, totals USD2.2 million. This payment is based on Fortumo's earnings before interest, tax, depreciation and amortisation performance in the year ended June 30, the company notes. Receives USD3.2 million balance in escrow for Fortumo acquisition last Friday. Boku acquired Fortumo and its subsidiaries on July 1, 2020.

----------

Focusrite PLC - High Wycombe, Buckinghamshire-based music and audio products company - Provides a trading update that indicates positive trading in its current financial year. Says revenue, profit, and cash flow have increased significantly in the year ended August 31. Expects revenue to total around GBP173 million in financial 2021, up from GBP130 million a year prior. Says improved performance is primarily due to strong customer demand and includes four-months of contribution from Sequential LLC, which the company acquired in April. Notes net cash balance of around GBP17 million on August 31 and says cash generation remains a priority.

----------

Sumo Group PLC - Sheffield, England-based video games company - Acquires Bristol-based video game developer and publisher Auroch Digital for a GBP6.0 million cash consideration. Plans to pay further deferred consideration, continent on Auroch's performance in the financial year due to end on March 31, 2024. Says the acquisition enhances its publishing capability. Notes Auroch's pipeline of original intellectual property and track record for developing innovative, high-quality games. This follows the launch of the company's publishing division, Secret Mode, in March. Sumo Group's chief executive Carl Cavers says that: "While this is a relatively small acquisition, it is a highly significant one for us strategically."

----------

Mercia Asset Management PLC - West Midlands-based asset manager - Says its fund management operations continue to perform well. assets under management total GBP940 million. Non-executive chair Ian Metcalfe says the company's "Group-wide strong liquidity position is enabling us to deploy capital into new and existing attractive investment opportunities, both through our managed funds and balance sheet. We have a differentiated business model which is now delivering incremental shareholder value and we are increasingly optimistic about our future."

----------

N4 Pharma PLC - Derbyshire-based pharmaceutical company developing Nuvec for cancer treatments and vaccines - Says initial testing of SARS-COV-2 plasmid and Nuvec cancer treatment show improved response in terms of transfection. Adds that the combination of these treatments showed a dose-related SARS-COV-2 Spike protein production. The company says: "These in vitro results provide a positive platform for the commencement of the in vivo work beginning this month which is expected to last six to eight weeks with an additional two to three weeks for analysis."

----------

Silver Bullet Data Services Group PLC - marketing consulting company based in London - Wins new contract to design and deploy a data strategy for Irish broadcasting company RTE. Plans to "optimise" RTE's business infrastructure to speed up its digital transformation. Says the contract will draw on Silver Bullet's experience assisting broadcasters to move towards digital advertising spending and away from linear TV advertising. Chief executive of Silver Bullet, Ian James, says: "We are delighted to be at the centre of the broadcaster and audio data-driven transformation industry...We look forward to seeing the results of this years' work as the digital video and audio market looks set to bounce back in 2022."

----------

IronRidge Resources Ltd - minerals exploration company with projects in Chad, Ghana and the Ivory Coast - Reports final high-grade lithium drill intersections at new targets adjacent to the Ewoyaa Lithium Project in Ghana. Notes highest metal content intersection discovered to date, specifically 53 metres at 1.3% lithium oxide from an 80 metre deep GRC0392 hole. Chief Executive Vincent Mascolo says: "The resource expansion drilling programme has now been completed and we will maintain momentum with five drill rigs currently active on site for the resource infill programme. The board remains confident the additional exploration targets will increase resource scale and improve project economics, where we have defined Ghana's first lithium JORC compliant resource of 14.5 [million tonnes] at [1.3% lithium oxide]."

----------

By Scarlett Butler; scarlettbutler@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
25 Apr 2024 11:56

N4 Pharma strikes partnership deal for intracellular delivery

(Alliance News) - N4 Pharma PLC on Thursday said it has entered into a collaboration agreement with SRI International Inc.

Read more
23 Apr 2024 13:32

IN BRIEF: N4 Pharma loss widens but "great optimism" remains

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company focused on the development of Nuvec - Posts revenue of GBP1,953 in 2023, compared to no revenue a year ago. Pretax loss widens to GBP1.4 million from GBP1.2 million. Looks ahead to the rest of 2024 with "great optimism."

Read more
18 Apr 2024 12:14

N4 Pharma sees potential in Nuvec delivery method for cancer treatment

(Alliance News) - N4 Pharma PLC on Thursday reported that its novel delivery system for cancer treatment has shown promise, after a successful trial.

Read more
15 Feb 2024 13:17

N4 Pharma shares jump on latest Nuvec developments

(Sharecast News) - N4 Pharma announced a significant advancement in the development of Nuvec, an innovative delivery system tailored for cancer treatments, gene therapy, and vaccines, on Thursday.

Read more
15 Feb 2024 12:06

IN BRIEF: N4 Pharma shares rise on "encouraging" Nuvec research

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company, focused on the development of Nuvec - Reports an "encouraging" update from its Nuvec delivery system for cancer treatments, gene therapy and vaccines. It has completed in-vitro experiments combining epidermal growth factor receptor and polo like kinase 1 molecules onto a Nuvec nanoparticle, before testing it on lung cancer cells. "The work clearly shows that there is a strong beneficial effect at 48 hours on cellular inhibition compared to single dose siRNA, by combining both EGFR and PLK1 onto the same particle," N4 says.

Read more
15 Feb 2024 10:52

AIM WINNERS & LOSERS: DSW warns on earnings amid tepid M&A markets

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
19 Jan 2024 13:00

N4 Pharma's Nuvec granted patent in India

(Sharecast News) - N4 Pharma, a pharmaceutical company developing the cancer vaccine delivery system Nuvec, announced on Friday that it has received confirmation from the University of Queensland regarding the granting of its patent for Nuvec in India.

Read more
19 Jan 2024 09:26

IN BRIEF: N4 Pharma gets India patent for medical delivery system

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company, focused on the development of Nuvec - University of Queensland has informed the company that it has been notified by its Indian patent attorney of the granting of its patent for Nuvec in India. Nuvec is a novel silica nanoparticle delivery system for cancer treatments, gene therapy and vaccines. N4 Pharma says the granted patent in India is for a composition of matter patent for the particle itself, alongside the manufacturing process relating to how the particle is made. Says it matches the patents granted in the US, Canada, Europe, Japan, Australia and China.

Read more
16 Jan 2024 14:05

N4 Pharma subsidiary agrees work programme for glaucoma treatment

(Sharecast News) - N4 Pharma announced a significant development through its subsidiary Nanogenics on Tuesday, after Nanogenics inked a contract to initiate the formulation and sequence selection work for its ECP105 product, aimed at pre-clinical studies at King's College, London.

Read more
16 Jan 2024 13:26

IN BRIEF: N4 Pharma touts contract to test glaucoma treatment, ECP105

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company, focused on the development of Nuvec, a novel silica nanoparticle delivery system, for vaccines and therapeutics - Says subsidiary, Nanogenics Ltd, has signed a contract to start the formulation and sequence selection work to prepare its ECP105 product for testing in pre-clinical studies at King's College, London.

Read more
8 Jan 2024 12:30

N4 Pharma reports progress in Nuvec clinical research

(Sharecast News) - Pharmaceutical delivery system developer N4 Pharma reported significant progress in its research efforts to enhance viral vector performance using Nuvec on Monday.

Read more
8 Jan 2024 09:11

N4 Pharma hails increased efficacy of Nuvec when complexed with AAV8

(Alliance News) - N4 Pharma PLC on Monday said that a series of experiments have shown that Nuvec can deliver increased transduction efficacy, when complexed with Adeno-Associated virus 8.

Read more
18 Dec 2023 16:55

LONDON MARKET CLOSE: FTSE 100 outperforms European peers

(Alliance News) - Stock prices in London closed higher on Monday, after investors shrugged off hawkish comments from US Federal Reserve officials amid festive cheer.

Read more
18 Dec 2023 12:43

N4 Pharma rises on successful results from Nuvec administration

(Alliance News) - N4 Pharma PLC on Monday announced the successful oral administration of Nuvec with a DNA plasmid after receiving promising results from its research programme with the University of Queensland.

Read more
18 Dec 2023 11:17

N4 Pharma upbeat on recent Nuvec developments

(Sharecast News) - N4 Pharma updated the market on Monday on its ongoing research efforts related to Nuvec, its delivery system designed for cancer treatments and vaccines.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.